|
 |
|||||||||||||||||||||||
|
 |
 |
 |
|
|
|||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||
 |
 |
 |
|
|||||||||||||||||||||
| |
|
|||||||||||||||||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
||
 |
 |
|
 |
|
 |
|
 |
|
 |
||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
PRODUCTS |
MULTIPLE SCLEROSIS OCULOMTRICITY IN MUTLIPLE SCLEROSIS MAIN OBSERVED OCULOMOTOR SYNDROMES IN MULTIPLE SCLEROSIS The Mobile EBT® can help you quantify most saccades-related indicators.
Multiple Sclerosis (MS) patients may display various purely oculomotor symptoms.   The lists of abnormalities represent trends and are neither exclusive nor exhaustive. MS patients also present cognitive disabilities impacting oculomotricity. Abnormalities have been reported in memory guided saccades (increased error rates and saccadic latency, decreased accuracy) and in anti-saccade tasks (increased saccadic latency and latency variability, correlation between error rates and PASAT scale).
OCULOMOTRICITY AND DIAGNOSIS OF MULTIPLE SCLEROSIS Multiple sclerosis (MS) diagnosis focuses on the objective demonstration of the dissemination of inflammatory white matter lesions in both time and space. MS cannot be diagnosed through a single test; its clinical diagnosis should be supported by laboratory and neuroimaging findings. Oculomotor impairment is reported in about 60% to 80% of MS patients. Visual symptoms are often early indicators of the disease in these patients.
However, oculomotor impairment investigation is usually done “by hand”, which proves clinically challenging. For instance, Frohman et al (2003) showed that internuclear ophthalmoplegia (INO) goes clinically undetected by 71%.
Mobile EBT® dramatically increases the power of such investigation by helping you detect or quantify oculomotor symptoms, including diplopia, in particular INO and saccadic dysmetria. Using Mobile EBT® for early oculomotor testing improves diagnosis in some MS-affected patients and sets up a landmark for monitoring disease evolution. Early diagnosis leads to immuno-modulatory treatment that may slow the rate of conversion to clinically definite multiple sclerosis. Oculomotor impaired MS patients have been shown to be sustainably more disabled than those with normal eye motility. The benefit of early treatment in these patients is consequently significant. OCULOMOTRICITY AND FOLLOW UP OF MULTIPLE SCLEROSIS Oculomotricity can also be used as a sensitive and quantified marker of eye movement abnormalities. For MS-affected patients in relapsing stage, eye movement abnormalities are relatively stable. Oculomotricity is a good marker to follow up the evolution of the pathology and can help monitor the effect of therapy in MS at any stage of the disease. This method can help chose the drug to prescribe to patients and its dosage.
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
